AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.


CEACAM1 antibodies for anti-viral therapy: immune response against viruses is specific and allows an application to a broad range of viruses.
Technology Benefits
Complementary anti-viral therapy Option
Applies to a broad range of viruses
Specific immune response against specific viruses
Technology Application
therapeutic development
Detailed Technology Description
The approach is based on a antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction. The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against influenza virus and cytomegalovirus.
Type of Cooperation
Application Date
Application No.
US201615221612 20160728
- international:
C07K16/28; C12N5/0783
- cooperative:
A61K38/177; A61K39/095; A61K39/102; A61K39/1045; C07K16/2803; C12N5/0638; C07K2317/24; C07K2317/565; C07K2317/75; C07K2317/76; C07K2317/92; C07K2319/30; C12N2501/58; Y02A50/466
Patent application
ID No.

For more information, please click Here
Mobile Device